BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...A led by Casdin Capital LLC. Also participating were fellow new investors NFX Capital, The Mark Foundation for Cancer Research...
BioCentury | Apr 23, 2020
Finance

RNA epigenetic cancer company Accent adds $63M in series B round

...the clinic. Existing investor EcoR1 Capital led the round. New investors GV, AbbVie Ventures, The Mark Foundation for Cancer Research...
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

...syndicate includes 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research...
...Investors: 20/20 HealthCare Partners, 3SBio Inc., Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...as psoriasis and atopic dermatitis. Discovery ND ND Sept. 2018 Evotec SE (Xetra:EVT) / The Mark Foundation for Cancer Research...
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...clinical R&D and David Stojdl as SVP of discovery research. Bernstein is CMO at The Mark Foundation for Cancer Research...
Items per page:
1 - 5 of 5
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...A led by Casdin Capital LLC. Also participating were fellow new investors NFX Capital, The Mark Foundation for Cancer Research...
BioCentury | Apr 23, 2020
Finance

RNA epigenetic cancer company Accent adds $63M in series B round

...the clinic. Existing investor EcoR1 Capital led the round. New investors GV, AbbVie Ventures, The Mark Foundation for Cancer Research...
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

...syndicate includes 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research...
...Investors: 20/20 HealthCare Partners, 3SBio Inc., Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...as psoriasis and atopic dermatitis. Discovery ND ND Sept. 2018 Evotec SE (Xetra:EVT) / The Mark Foundation for Cancer Research...
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...clinical R&D and David Stojdl as SVP of discovery research. Bernstein is CMO at The Mark Foundation for Cancer Research...
Items per page:
1 - 5 of 5